Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + magnesium is a combination of two agents—lidocaine, an amide-type local anesthetic and antiarrhythmic, and magnesium (typically administered as magnesium sulfate), an essential mineral with neuromodulatory properties. This combination is used intravenously in perioperative settings for multimodal anesthesia or for the management of intractable neuropathic pain. Lidocaine acts primarily by blocking voltage-gated sodium channels on neuronal membranes, stabilizing them and inhibiting the initiation and conduction of nerve impulses. Magnesium exerts analgesic effects mainly through antagonism of N-methyl-D-aspartate (NMDA) receptors, reducing central sensitization to pain. When combined, these drugs have been shown to provide opioid-sparing effects during surgery, improve hemodynamic stability under general anesthesia without prolonging neuromuscular blockade recovery time beyond that caused by magnesium alone, and offer relief in cases of refractory neuropathic pain such as trigeminal neuralgia[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + magnesium.